National 12th Five-Year Science and Technology Support Plan(No.2013BAI02B01);National Key Science and Technology Project of"Major New Drug Creation"(No.2019ZX09201005-002-006);Beijing TCM Science and Technology Development Fund Project(No.JJ-2020-79);Science and Technology Innovation Project of China Academy of Chinese Medical Sciences(No.CI2021A00920)。
Objective:To systemically evaluate clinical efficacy and safety of traditional Chinese medicine(TCM)combined with ivabradine(IVA)in the treatment of chronic heart failure(CHF).Method:We searched China National Knowled...
the National Natural Science Foundation Youth Science Foundation(No.81601661);the Science Foundation for Post-doctoral researchers in Anhui Province of China(No.2016B140).
Post-resuscitation myocardial dysfunction(PRMD)is the most severe myocardial ischemia-reperfusion injury(MIRI)and is characterized by difficult treatment and poor prognosis.Research has shown the protective effects of...
Objective: To observe the effectiveness and safety of ivabradine in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and heart failure. Methods:Patients who were admitted to hospital ...
Background: Junctional ectopic tachycardia (JET) is one troublesome supraventricular arrhythmia in postoperative pediatric cardiac surgical patients. Unless treated timely and effectively it may lead to morbidity and ...
Objective:To investigate the effects of ivabradine on Notch and NF-kappa B signaling pathway in myocardial cells of rats with myocardial infarction.Methods: The model of myocardial infarction was established by ligati...
The Systolic Heart failure treatment with the I( inhibitor ivabradine Trial (SHIFT, n = 6505) evaluated patients with symptomatic chronic heart failure (CHF), in sinus rhythm with resting heart rate ≥70 beats/min and...
Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15...
As a novel heart rate lowing agent, ivabradine can reduce the heart rate by inhibiting the If (pacemaker) current in the sinoatrial node without affecting blood pressure or left ventricular systolic function. Howeve...
AIM To perform a systematic-review and meta-analysis to compare outcomes of ivabradine combined with betablocker to beta-blocker alone in heart failure with reduced ejection fraction(HFr EF).METHODS We searched PubM e...